Zanzalintinib
Highest phase reached
Phase 3
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Small molecule
- Drug name
- Zanzalintinib
- Molecular weight
- 528.54
- Structure (SMILES)
- CNC(=O)c1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)ccnc2cc1OC
- xl 092
- Xl 092
- XL-092
- xl092
- XL092
- zanzalintinib
- Zanzalintinib
- zanzalintinib [INN]
- ZANZALINTINIB [USAN]
- Zanzalintinib [WHO-DD]
- zanzalintinib inn
- zanzalintinib usan
- zanzalintinib who dd
- CAS registry numbers
- 2367004-54-2
- ChEMBL ID
- CHEMBL5314428
- InChIKey
- JSPCKALGNNVYOO-UHFFFAOYSA-N
- PubChem compound IDs
- 139350422
- FDA ingredient codes (UNII)
- KC2JC2ZA04
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- zanzalintinib
- Type
- Synthetic organic
- Drug name stem
- -tinib
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- MET proto-oncogene, receptor tyrosine kinase
- Gene symbol
- MET
- Protein identifier
- P08581
- Median affinity
- 8
- Affinity units
- pIC50
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- AXL receptor tyrosine kinase
- Gene symbol
- AXL
- Protein identifier
- P30530
- Median affinity
- 8
- Affinity units
- pIC50
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- MER proto-oncogene, tyrosine kinase
- Gene symbol
- MERTK
- Protein identifier
- Q12866
- Median affinity
- 8
- Affinity units
- pIC50
- Condition
- Carcinoma, Squamous Cell
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000181
- Subject identifier
- D002294
- Condition
- Carcinoma, Renal Cell
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000349
- Subject identifier
- D002292
- Condition
- Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Carcinoma, Renal Cell
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000681
- Subject identifier
- D002292
- Condition
- Carcinoma, Non-Small-Cell Lung
- Highest recorded phase
- 1
- Condition identifier
- EFO:0003060
- Subject identifier
- D002289
- Condition
- Carcinoma, Renal Cell
- Highest recorded phase
- 3
- Condition identifier
- EFO:0005708
- Subject identifier
- D002292
- Condition
- Colorectal Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0005575
- Subject identifier
- D015179
- Condition identifier
- EFO_0000181
- Condition identifier
- EFO_0000349
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000616
- Condition identifier
- EFO_0000681
- Highest recorded phase
- 3
- Condition identifier
- EFO_0005708
- Highest recorded phase
- 1
- Condition identifier
- EFO_1001480
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0002142
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0002715
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0004958
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005005
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005040
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005058
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005060
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005070
- Condition identifier
- MONDO_0005086
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005102
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005233
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005549
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005575
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0006329
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0006382
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0006468
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0007256
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0008315
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0008977
- Highest recorded phase
- 2
And 12 more, listed on the interactive page.
- NCT03337698
- NCT05425940
- NCT05678673
- NCT06082167
- NCT06191796
- Hydrogen bond acceptors
- 6
- Hydrogen bond donors
- 3
- Polar surface area
- 118.65
- Calculated partition coefficient (ALogP)
- 4.89
- Calculated partition coefficient (XLogP)
- 4.7
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 1
- Rotatable bonds
- 8
- Heavy atoms
- 39
- Molecular formula
- C29H25FN4O5
- Monoisotopic mass
- 528.18089807
- Natural product
- No
- Recorded assays
- 116
- Active assays
- 10
Active assay types
- Confirmatory
Related records
Trials (49)
- A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)
- A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
- A Phase 2 Multicenter Single-Arm Clinical Trial of Zanzalintinib and Pembrolizumab in Subjects With Resectable Clear Cell Renal Cell Carcinoma
- A Phase 2 Study Of Zanzalintinib For Patients With Recurrent Or Metastatic Olfactory Neuroblastoma
- A Phase 2 Trial of Zanzalintinib in Advanced/Metastatic Bone Sarcomas (ZAMBONE)
- A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)
- A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors
- A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
- A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma
- Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC
- H&N NEO-COMBAT XL: Neoadjuvant XL-092 (Zanzalintinib) and Pembrolizumab (Keytruda) in Surgically Resectable, HPV Negative Oral Cavity Squamous Cell Carcinoma (OCSCC)
- Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study
- Maintenance Zanzalintinib and Durvalumab in Participants With Advanced Hepatocellular Cancer
- Maintenance Zanzalintinib With Etoposide After HDCT in GCT
- Neoadjuvant Zanzalintinib Plus Nivolumab in Patients With Locally Advanced and/or Inoperable Clear Cell Renal Cell Carcinoma With or Without Non-measurable Metastasis
- NIMBLE-CRC: NeoImmunoModulation Before Leveraging Excision in Colorectal Rectal Cancer
- Pharmacokinetics (PK) and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment (HI)
- Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue Sarcoma
- Phase II Trial of Zanzalitinib in Patients With Metastatic Castration Resistant Prostate Cancer
- Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer
In development for (8)
- Bone sarcoma Phase 2
- Clear cell renal carcinoma Phase 3
- Colorectal cancer Phase 3
- Head and neck squamous cell carcinoma Phase 2
- Neoplasm Phase 2
- Non-small cell lung carcinoma Phase 1
- Renal cell adenocarcinoma Phase 3
- Renal cell carcinoma Phase 3